Phase 4 N=72 Empagliflozin and Hepatic Glucose Metabolism
Hepatic Glucose Metabolism
Primary: Effect of Empagliflozin on Autonomic Nervous System — 480; 621; 355; 635 ng/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 Post-Prandial Liver Glucose Metabolism in PCOS
Polycystic Ovarian Syndrome · Obesity · Hepatic Steatosis
Primary: Hepatic Fat Fraction — 8.35 Percent
Phase 3 N=30 Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin
Type II; Diabetes
Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl
N/A N=20 Hepatic Mitochondrial Function in Youth
Hepatic Steatosis · Bariatric Surgery Candidate · Adolescent Obesity
Primary: Change in Percentage of Liver Fat Per MRI — -13.93 percentage of liver fat
Phase 3 N=12 The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
Healthy
Primary: Endogenous Glucose Production (EGP) — 4.99; 5.02; 6.82; 5.52 umol/kg/min
Phase 1 N=10 The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA
Healthy Participants
Primary: Rates of Hepatic Mitochondrial Oxidation — 262; 149 micromol/min
N/A N=23 Aldosterone and Glucose Homeostasis
Diabetes Mellitus
Primary: Insulin Secretion — 48.9; 37.6; 51.8; 34.4 uU/mL
Phase 4 N=36 Effects of Metformin on Hepatic FFA Metabolism
Type 2 Diabetes · Dyslipidemia
Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min
Phase 4 N=32 Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Diabetes Mellitus, Type 2
Primary: Endogenous Glucose Production Measurement — 155; 121; 104; 98 mg/dl
Phase 4 N=5 Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
Hepatitis B
Primary: Differences in Blood Glucose Levels as Measured by GNS-POC, GS-POC and Venous Blood Prior to and After HBIG Injection — -3.2; 6.0; 56.6; -2.6 mg/dL — p=0.59
N/A N=12 Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
Type 1 Diabetes Mellitus
Primary: Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration — 6.5 g/L
Phase 2 N=10 Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla
Type 1 Diabetes
Primary: Brain Glycogen Turnover Rate — 0.31; 0.28 mg/kg/min
Phase 4 N=164 Study of Glycemic Control on Liver Transplantation Outcomes
Evidence of Liver Transplantation · Hyperglycemia · Rejection
Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709
Phase 4 N=16 Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM
Diabetes
Primary: Objective: Comparisons of the Effects of Co-administration of Sitagliptin and Metformin Alone or in Combination Versus Placebo on Baseline Endogenous Glucose Production…
N/A N=29 Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes
Diabetes Mellitus · Diabetes Mellitus, Type 2
Primary: Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes — 8.2; 9.4; 17.4; 15.6 umol/kgFFM/min
N/A N=82 Fructose Consumption and Metabolic Dysregulation
Central Obesity · Hypertriglyceridemia
Primary: TG Plasma AUC — 1130; 1220 mmol/l*min — p=0.005
Phase 3 N=30 SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
Type II Diabetes Mellitus
Primary: Change in Plasma Glucose Concentration — -29.7; -17.2; 3.1; 0.9 mg/dl
N/A N=60 Mechanisms of Glucose Lowering Effect of Colesevelam HCl
Diabetes
Primary: Fasting Endogenous Glucose Production (EGP) — 0.19; 1.59 umol per kg Fat-Free Mass (FFM) per min — p=<0.1
Phase 4 N=100 Intraoperative Glucose Control in Liver Transplant
Liver Transplant
Primary: Infection Rates — 27; 26; 11; 7 Participants — p=0.841
Phase 2 N=53 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
N/A N=26 Incretin Effect in People With Impaired Fasting Glucose
Obesity
Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min
Phase 1 N=22 Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146
N/A N=9 Effect of Sucrose on Liver Fat
Healthy Volunteers
Primary: Percentage Change in Liver Fat — 1.9; 1.9 percentage of change — p=0.390
N/A N=11 Physiologic Response to Glucagon at Varying Insulin Levels
Type 1 Diabetes Mellitus
Primary: Area Under the Curve for Glucose Above Baseline — 0.623; 0.59; 0.03 mg/kg glucose per mcg glucagon
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 4 N=44 Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism
Metabolic Syndrome
Primary: Insulin Secretion — 293.1; 234.7; 330.8; 300.4 uU/mL*10min
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Phase 3 N=92 Liver and Fat Regulation in Overweight Adolescent Girls
Hepatic Steatosis · Polycystic Ovarian Syndrome · Obesity
Primary: Hepatic Glucose Release — 1.85; 1.46; 1.54; 1.88 mg/kg/min
N/A N=39 Change of Fructose to Fat in South Asians
Elevated Triglycerides · Diabetes · Cardiovascular Disease
Primary: Fold Change in Plasma Very Low Density Lipoprotein (VLDL) Triglyceride Palmitate — 1.24; 1.85 fold change — p=0.05
N/A N=44 Effect of Fermentable Carbohydrate on Glucose Homeostasis
Prediabetes
Primary: Glycaemic Control — -0.23; 0.44 mmol//l — p=0.005